-
Article
Open AccessReply to: Vitamin C as a promoter of γδ T cells
-
Article
Open AccessAllogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer
Vγ9Vδ2 T cells are promising candidates for cellular tumor immunotherapy. Due to their HLA-independent mode of action, allogeneic Vγ9Vδ2 T cells can be considered for clinical application. To apply allogeneic ...
-
Article
Open AccessCorrection to: Cancer immunotherapy with γδ T cells: many paths ahead of us
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Article
Open AccessCancer immunotherapy with γδ T cells: many paths ahead of us
γδ T cells play uniquely important roles in stress surveillance and immunity for infections and carcinogenesis. Human γδ T cells recognize and kill transformed cells independently of human leukocyte antigen (H...
-
Article
Open AccessVitamin C promotes the proliferation and effector functions of human γδ T cells
γδ T cells are of interest as effector cells for cellular immunotherapy due to their HLA-non-restricted lysis of many different tumor cell types. Potential applications include the adoptive transfer of in vitr...
-
Article
Open AccessVitamin C supports conversion of human γδ T cells into FOXP3-expressing regulatory cells by epigenetic regulation
Human γδ T cells are potent cytotoxic effector cells, produce a variety of cytokines, and can acquire regulatory activity. Induction of FOXP3, the key transcription factor of regulatory T cells (Treg), by TGF-...
